Special Issue

Cardiovascular Diseases in the Era of Precision Medicine

Message from the Guest Editors

This Special Issue aims to highlight the latest advancements in the detection, treatment and management of cardiovascular diseases through the application of precision medicine. We welcome submissions that delve into aspects of experimental and laboratory medicine, focusing on the innovative methodologies and technologies driving personalized cardiovascular care. The scope of this Specail Issue includes, but is not limited to, the following topics:

Cutting-edge diagnostic tools and techniques tailored to individual patient profiles.

Biosignal and other big data analysis for the detection and prediction of cardiovascular conditions.

The application of genomics, proteomics and metabolomics in developing personalized cardiovascular treatments.

Advances in imaging technologies for accurate and detailed cardiovascular assessments.

Personalized therapeutic strategies and their impact on patient outcomes.

The integration of multi-omics data to enhance our understanding and treatment of cardiovascular diseases.

Guest Editors

Dr. Panteleimon Pantelidis

School of Medicine, National & Kapodistrian University of Athens, Athens, Greece

Dr. Polychronis E. Dilaveris

School of Medicine, National & Kapodistrian University of Athens, Athens. Greece

Deadline for manuscript submissions

closed (30 September 2025)



Biomedicines

an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed



mdpi.com/si/213380

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +4161 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines





an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed





About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access iournal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

- Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
- 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).